Trius Therapeutics, Inc. Prices Public Offering of Common Stock

Trius Therapeutics, Inc. Prices Public Offering of Common Stock

SAN DIEGO, Jan. 18, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc.
(Nasdaq:TSRX) today announced the pricing of an underwritten public offering
of 6,300,000 shares of its common stock at a price to the public of $4.75 per
share. The gross proceeds to Trius from this offering are expected to be
approximately $29,925,000 million, before deducting underwriting discounts and
commissions and other estimated offering expenses payable by Trius. The
offering is expected to close on or about January 24, 2013, subject to
customary closing conditions.

Citigroup and Leerink Swann are acting as joint book-running managers and
Baird is acting as a co-lead manager in the offering. Trius has granted the
underwriters a 30-day option to purchase up to an aggregate of 945,000
additional shares of common stock. Trius anticipates using the net proceeds
from the offering for general corporate purposes, including clinical trial,
preclinical and other research and development expenses, capital expenditures,
working capital and general and administrative expenses.

The securities described above are being offered by Trius pursuant to two
shelf registration statements previously filed with and declared effective by
the Securities and Exchange Commission (the "SEC")onSeptember 15, 2011 and
September 11, 2012. Preliminary prospectus supplements related to the offering
have been filed with theSECand are available on the SEC's website at Copies of the final prospectus supplements and
accompanying prospectuses relating to these securities may also be obtained,
when available, from Citigroup, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, via telephone at 1-800-831-9146 or email at or from Leerink Swann LLC, Attention: Syndicate
Department, One Federal Street, 37^th Floor, Boston, MA 02110, via telephone
at 1-800-808-7525 or email at This press release shall
not constitute an offer to sell or the solicitation of an offer to buy these
securities, nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of any
such state or other jurisdiction.

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the
discovery and development of innovative antibiotics for serious infections.
The company's lead investigational drug, tedizolid phosphate, is a once daily,
IV and orally administered second generation oxazolidinone in Phase 3 clinical
development for the treatment of serious gram-positive infections, including
those caused by methicillin-resistant Staphylococcus aureus (MRSA). Trius has
partnered with Bayer HealthCare for the development and commercialization of
tedizolid phosphate outside of the U.S., Canada and the European Union. In
addition to the company's tedizolid phosphate clinical program, Trius has
initiated IND-enabling studies for its Gyrase-B development candidate with
potent activity against Gram-negative bacterial pathogens including multi-drug
resistant strains of E. coli, Klebsiella, Acinetobacter and Pseudomonas.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such statements are
subject to risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such statements
include, but are not limited to, Trius' expectations regarding the closing of
the public offering and the expected gross proceeds therefrom. Among the
factors that could cause actual results to differ materially from those
indicated in the forward-looking statements are risks and uncertainties
associated with market conditions and the satisfaction of customary closing
conditions related to the offering, as well as risks and uncertainties
associated with Trius' business and finances in general, and the other risks
described in Trius' Quarterly Report on Form 10-Q for the quarter ended
September 30, 2012, and in the preliminary prospectus supplements related to
the offering filed with the SEC. All forward-looking statements contained in
this press release speak only as of the date on which they were made. Trius
undertakes no obligation to update such statements to reflect events that
occur or circumstances that exist after the date on which they were made.

CONTACT: Public Relations Contact:
         Laura Kempke/Andrew Law at MSLGROUP
         Investor Relations Contact:
         Stefan Loren at Westwicke Partners, LLC
Press spacebar to pause and continue. Press esc to stop.